Citations

Clear

16281 citation(s) found for "Yu, David".

Evaluating the Effect of Alzheimer's Disease‐Related Biomarker Change in Corticobasal Syndrome and Progressive Supranuclear Palsy
García‐Cordero, Indira , Anastassiadis, Chloe , Khoja, Abeer , Morales‐Rivero, Alonso , Thapa, Simrika, Vasilevskaya, Anna , Davenport, Carly, Sumra, Vishaal , Couto, Blas , Multani, Namita, Anor, Cassandra Jessica, Misquitta, Karen , Heuer, Hilary W. , Tang‐Wai, David F. , Dickerson, Bradford, Ljubenkov, Peter A. , Huey, Edward D. , Kovács, Gábor G. , Boxer, Adam L. , Taghdiri, Foad , Tartaglia, Maria Carmela , Kovacs, Gabor G , VandeVrede, Lawren , Pantelyat, Alexander , Litvan, Irene , Boeve, Bradley F. , Rojas, Julio C. , Fox, Susan H. , Lang, Anthony E.

Mayo Clinic

Annals of Neurology | April 5, 2024 | Volume: 96 | Issue: 1 | Pages: 99-109

10.1002/ana.26930 | PMID 38578117 Get It

ObjectivesTo evaluate the effect of Alzheimer's disease (AD) ‐related biomarker change on clinical features, brain atrophy and functional connectivity of patients with corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP).MethodsData from patients with a clinical diagnosis of CBS, PSP, and AD and healthy controls were obtained from the 4‐R‐Tauopathy Neuroimaging Initiative 1 and 2, the Alzheimer's Disease Neuroimaging Initiative, and a local cohort from the Toronto Western Hospital. Patients with CBS and PSP were divided into AD‐positive (CBS/PSP‐AD) and AD‐negative (CBS/PSP‐noAD) groups based on fluid biomarkers and amyloid PET scans. Cognitive, motor, and depression scores; AD fluid biomarkers (cerebrospinal p‐tau, t‐tau, and amyloid‐beta, and plasma ptau‐217); and neuroimaging data (amyloid PET, MRI and fMRI) were collected. Clinical features, whole‐brain gray matter volume and functional networks connectivity were compared across groups.ResultsData were analyzed from 87 CBS/PSP‐noAD and 23 CBS/PSP‐AD, 18 AD, and 30 healthy controls. CBS/PSP‐noAD showed worse performance in comparison to CBS/PSP‐AD in the PSPRS [mean(SD): 34.8(15.8) vs 23.3(11.6)] and the UPDRS scores [mean(SD): 34.2(17.0) vs 21.8(13.3)]. CBS/PSP‐AD demonstrated atrophy in AD signature areas and brainstem, while CBS/PSP‐noAD patients displayed atrophy in frontal and temporal areas, globus pallidus, and brainstem compared to healthy controls. The default mode network showed greatest disconnection in CBS/PSP‐AD compared with CBS/PSP‐no AD and controls. The thalamic network connectivity was most affected in CBS/PSP‐noAD.InterpretationAD biomarker positivity may modulate the clinical presentation of CBS/PSP, with evidence of distinctive structural and functional brain changes associated with the AD pathology/co‐pathology. ANN NEUROL 2024;96:99–109
BPI24-017: Optimizing the Implementation of New Therapies in Multiple Myeloma
Cole, Craig E. , Vesole, David H. , Stanley, Mary, Demirhan, Kimberly , Shivakumar, Latha, Hanna, Kirollos S. , Plotkin, Elana

Mayo Clinic

Journal of the National Comprehensive Cancer Network | April 5, 2024 | Volume: 22 | Issue: 2.5 | Pages: No page available

10.6004/jnccn.2023.7184 Get It

Abstract LB334: Mechanisms of endocrine resistance to letrozole, fulvestrant, and palbociclib are associated with increased sensitivity to hexyl-cuban-1-yl biguanide inhibitors of CYP3A4 mediated epoxyeicosatrienoic acid biosynthesis
Guo, Zhijun , Lei, Jianxun, Makovec, Allison , Hawse, John R. , Ambrose, Elizabeth A. , D'Assoro, Tony, Matthew, Goetz P., Makovec, Allison , Jayaraman, Swaathi , Lange, Carol Ann , Georg, Gunda I. , Potter, David A.

Mayo Clinic

Cancer Research | April 5, 2024 | Volume: 84 | Issue: 7_Supplement | Pages: LB334-LB334

10.1158/1538-7445.am2024-lb334 Get It

Abstract Introduction: Eicosanoid mediated mechanisms of hormone therapy resistance in ER+HER2- breast cancer are poorly understood. Cytochrome P450 arachidonic acid (AA) epoxygenase-derived epoxyeicosatrienoic acids (EETs) contribute to breast cancer progression by promoting mitochondrial oxidative phosphorylation (OXPHOS). However, it remains unclear how EETs contribute to hormonal therapy resistance. In this study, the well-known letrozole resistant (LR) MCF-7 AC1 cell line overexpressing aromatase was selected for fulvestrant resistance (FR). A clonal cell line resistant to letrozole and fulvestrant (LR/FR) also exhibited resistance to palbociclib (PR) (MCF-7 AC1 LR/FR/PR). Xenograft tumors of this cell line were resistant to letrozole, fulvestrant, and palbociclib. Structure activity studies and modeling led to the development of CYP3A4 AA epoxygenase inhibiting biguanides hexyl cuban-1-yl biguanide (HCB) and fluorinated hexyl derivatives C5F2-HCB and C6F3-HCB. Fluorination on the hexyl moiety led to broader inhibition of EET regioisomer biosynthesis. These agents were tested for inhibition of proliferation, signaling, and OXPHOS/glycolysis balance in the MCF-7 AC1 LR/FR/PR cell line. Results: In the MCF-7 AC1 LR/FR/PR clonal cell line cyclin D1 and estrogen receptor (ER) expression were undetectable, while cyclin E1, CDK4, CDK6, CYP3A4, and c-MYC were upregulated 11, 40, 13, 10, and 12- fold (n=3, p<0.001) compared to the MCF-7 cell line. LC-MS analysis demonstrated 1.8, 1.4, and 1.2- fold higher total cellular levels of (±)8,9, (±)11,12, and (±)14,15-EET in the MCF-7 AC1 LR/FR/PR cell line compared to the MCF-7 cell line (n=3, p<0.05). C6F3-HCB suppressed cellular levels of EETs: (±)8,9-EET by 55% (n=3, p<0.031), (±)11,12-EET by 53% (n=3, p<0.029), and (±)14,15-EET by 60% (n=3, P<0.0001). The MCF-7 AC1 LR/FR/PR cell line was more potently inhibited by hexyl-cuban-1-yl biguanides compared to the MCF-7 cell line, exhibiting lower IC50 values (MCF-7 AC1 LR/FR/PR IC50 vs. MCF-7 IC50; HCB 4.1 vs. 7.0 uM; for C5F2-HCB 10 vs. 25 uM; C6F3-HCB: 5.4 vs. 12 uM; P values all <0.05). Measurement of spare respiratory capacity revealed that the MCF-7 AC1 LR/FR/PR cell line had 4.2% spare respiratory capacity compared to 34% for MCF-7, indicating a lower OXPHOS reserve for the resistant cells. Additionally, the MCF-7 AC1 LR/FR/PR cell line displayed a 2.4-fold higher extracellular acidification rate (ECAR) than the MCF-7 cell line, indicating a higher glycolysis rate (Warburg effect) in the resistant cells. Conclusion: Selection for fulvestrant resistance of MCF-7 AC1 cells resulted in upregulation of CYP3A4 and biosynthesis of hormone therapy resistance associated EETs while correlating with greater sensitivity to fluorinated hexyl-cuban-1-yl biguanides that inhibit EET biosynthesis. Citation Format: Zhijun Guo, Jianxun Lei, Allison Makovec, Swaathi Jayaraman, John R. Hawse, Carol Lange, Elizabeth Ambrose, Gunda I. Georg, Tony D'Assoro, Goetz P. Matthew, David A. Potter. Mechanisms of endocrine resistance to letrozole, fulvestrant, and palbociclib are associated with increased sensitivity to hexyl-cuban-1-yl biguanide inhibitors of CYP3A4 mediated epoxyeicosatrienoic acid biosynthesis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl):Abstract nr LB334.
Abstract CT225: Quantitative assessment of PSMA imaging before and after 177Lu-PSMA-617 treatment in a Ph I/II trial
Nauseef, Jones T. , Thomas, Charlene , Sun, Michael, Jacobs, Nicole , Rüder, S, Fernandez, Escarleth, Davidson, Zachary, Patel, Amie , Vallabhajosula, Shankar , Molina, Ana M. , Nanus, David M. , Castellanos, Sandra Huicochea , Bander, Neil H. , Jacobs, Nicole, Ricaurte‐Fajardo, Andres , Sartor, Oliver , Sternberg, Cora N , Osborne, Joseph R. , Perk, Timothy , Tagawa, Scott T.

Mayo Clinic

Cancer Research | April 5, 2024 | Volume: 84 | Issue: 7_Supplement | Pages: CT225-CT225

10.1158/1538-7445.am2024-ct225 Get It

Abstract Background: We have previously reported that 177Lu-PSMA-617 given as a single-cycle, dose-intense regimen for patients (pts) with pretreated mCRPC is efficacious even without selection by PSMA (ESMO 2021). Quantitative analyses of pre-treatment PSMA PET may allow for better patient selection and prediction of toxicities. Analyses of sequential PET images may also provide insights that may be associated with longer term outcomes. Our previous analysis of 13 patients demonstrated association of PSMA PET signal with overall survival (OS) and PSA responses, as well as trends with adverse events (Nauseef GU ASCO 2022). Here we present long-term follow up data and expanded imaging correlatives from our completed phase I/II study. MethodsEntry criteria: progressive mCRPC after at least one prior potent AR pathway inhibitor and prior chemotherapy (excepting men ineligible for or refusing of chemotherapy) with allowance for prior radionuclides (incl. Ra223 and PSMA-TRTs). Treatment was fractionated-dose (D1 and D15) 177Lu-PSMA-617 (7.4-22.2 GBq). TRAQinform IQ (AIQ Solutions) was used to identify, track, and quantify regions of interest suspicious of cancer (lesion-ROI) on PSMA PET/CT images and quantify uptake in normal organs outside of lesion-ROI. Measurements included SUVmean across all lesion-ROI, volume of lesion-ROI, and SUVtotal (sum of SUV in all lesion-ROI), as well as changes after treatment, including in PSMA-expressing healthy tissues. Associations with survival were tested via Cox proportional hazard models in univariate analyses and associations with adverse events (AEs) and PSA responses were via assessed via Wilcoxon rank sum tests. Results32 pts (of 50 total in the study between 1/2017-2/2021) had pre- and post-treatment imaging suitable TRAQinform IQ analysis and associated survival analyses. Baseline characteristics were similar to the entire study cohort. PSA response of 50% was observed in 21/32 (66%) of which 16 were confirmed. No imaging variable predicted PSA30 or PSA50, although an association was observed in pretreatment SUVmean and lesion-ROI volume reduction. No imaging variable was significantly associated with OS (e.g., pretx SUVmean HR 0.9, p=0.10, pretx Volume HR 1.00, p=0.052). Pretx SUVmean was associated with mPFS (HR 0.85, 95% CI 0.74, 0.98, p=0.023). Among select AEs, anemia was associated with non-lesion-ROI skeleton SUVtotal in pre- (p=0.027) and post-tx (p=0.007). Higher pre-treatment salivary gland uptake (SUVmean) was associated with more xerostomia (p=0.11). Fatigue was associated with a variety of variables including salivary SUVs (mean, max, and total) and post-tx bowel SUVmax (p=0.030). ConclusionsPre-treatment and pre- to post-treatment 68Ga-PSMA11-PET data analyzed may be associated with outcome. While a strength of this study is the prospective nature of patient enrollment and fixed imaging timepoints, our associations are limited by small sample size. Expansion of this analysis to larger datasets may improve our ability to predict treatment response and toxicity by body-wide PSMA detection. Citation Format: Jones Trevor Nauseef, Charlene Thomas, Michael Sun, Nicole Jacobs, Andrés Ricaurte Fajardo, Sam Ruder, Escarleth Fernandez, Zachary Davidson, Amie Patel, A. Oliver Sartor, Shankar Vallabhajosula, Ana Molina, Cora N. Sternberg, David M. Nanus, Sandra Huicochea Castellanos, Joseph Osborne, Neil H. Bander, Timothy Perk, Scott Tagawa. Quantitative assessment of PSMA imaging before and after 177Lu-PSMA-617 treatment in a Ph I/II trial [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl):Abstract nr CT225.
Abstract CT243: Primary analysis of the Phase 2 ELM-2 study: Odronextamab in patients (pts) with relapsed/refractory follicular lymphoma (R/R FL)
Novelli, Silvana , Poon, Michelle, Guidez, Stéphanie , Jagadeesh, Deepa , Mayer, L, Tani, Monica , Cai, Jingxian, Uppala, Amulya , Shariff, Saleem, Brouwer‐Visser, Jurriaan , Chaudhry, Aafia, Ambati, Srikanth, Mussetti, Alberto , Mussetti, Alberto , Chong, Geoffrey , Taszner, Michał , Cho, Seok‐Goo , Villasboas, José C. , Ubieto, Ana Jiménez , Tessoulin, Benoit , Tucker, David , Walewski, Jan , Song, Yuqin , Bachy, Emmanuel , Alonso, Aránzazu , Luminari, Stefano , Iskierka‐Jazdzewska, Elżbieta , Mohamed, Hesham , Kim, Tae Min

Mayo Clinic

Cancer Research | April 5, 2024 | Volume: 84 | Issue: 7_Supplement | Pages: CT243-CT243

10.1158/1538-7445.am2024-ct243 Get It

Abstract Background: R/R FL is an incurable disease and outcomes worsen with successive relapses. A high unmet need remains for therapies that improve tumor control and extend survival after relapse. Odronextamab, an off-the-shelf CD20×CD3 bispecific antibody, demonstrated compelling efficacy, generally manageable safety, and maintenance of pt-reported overall quality of life scores from baseline in an interim analysis of the ELM-2 study (NCT03888105) in heavily pretreated pts with R/R FL (Villasboas et al. ASH 2023). Here, for the first time, we present the primary analysis of R/R FL in ELM-2. Methods: IV odronextamab was administered in 21-day cycles (C) until disease progression/unacceptable toxicity. Steroid prophylaxis and step-up dosing (0.7/4/20 mg) were used in C1 to mitigate the risk of cytokine release syndrome (CRS), followed by 80 mg on Days (D) 1, 8, and 15 of C2-4. Maintenance dosing continued at 160 mg Q2W, or Q4W if complete response (CR) was durable for 9 months (mo). Primary endpoint was objective response rate (ORR) per Lugano criteria by independent central review (ICR). Secondary endpoints included CR rate, duration of response (DOR), progression-free survival (PFS), and overall survival (OS). Primary analysis was performed when 128 pts had ≥52 weeks’ follow-up. Results: At data cutoff (Oct 20, 2023), 128 pts with FL Grade (Gr) 1-3a were evaluable for efficacy and safety: median age 61 yrs (range 22-84); FLIPI risk score 3-5 57.8%; POD24 49.2%; median 3 prior lines of therapy (2-13); 71.9% refractory to last treatment (Tx); 74.2% refractory to an anti-CD20 antibody. The median no. of Tx cycles was 19.4 (0.1-95.9); 95.3% and 85.2% of pts completed C1 and C4, respectively.Median efficacy follow-up was 20.1 mo; ORR was 80.5% and CR rate was 73.4% confirmed by ICR. Responses were durable (median DOR 22.6 mo; median DOCR 25.1 mo). Median PFS was 20.7 mo and 24-mo PFS was 46.1%. Median OS was not reached and 24-mo OS was 70.1%.The odronextamab safety profile was generally manageable and consistent with previous reports. Tx-emergent adverse events (AEs) occurred in all pts (Gr ≥3 85.9%); 15.6% had AEs leading to Tx discontinuation. With 0.7/4/20 mg step up (n=60), CRS events were mostly low grade (Gr 1 45.0%; Gr 2 10.0%; Gr 3 in 1 pt), occurred mostly in C1, and resolved in a median of 2 days; ICANS was reported in 1 pt (Gr 2). Infection rates were consistent with heavily pretreated, immunosuppressed pts (Leonard et al. JCO 2019; Hayne et al. BBMT 2020), occurring in 79.7% (102/128) of pts (Gr 4/5 14.0%; COVID-19 36.7% [Gr 5 6.3%]).Conclusion: Odronextamab demonstrated deep and durable responses in heavily pretreated pts with R/R FL; 91% of responders achieved CR, correlating with favorable PFS and OS at 24 mo. Odronextamab had a generally manageable safety profile and a low incidence of Gr 3 CRS/ICANS. Odronextamab could offer an important off-the-shelf Tx option for pts with heavily pretreated R/R FL. Citation Format: Geoffrey Chong, Michal Taszner, Silvana Novelli, Seok-Goo Cho, Jose C. Villasboas, Ana Jiménez Ubieto, Benoît Tessoulin, Michelle Poon, David Tucker, Jan Walewski, Yuqin Song, Emmanuel Bachy, Stephanie Guidez, Aranzazu Alonso, Deepa Jagadeesh, Stefano Luminari, Laura Magnano Mayer, Elżbieta Iskierka-Jażdżewska, Monica Tani, Jingxian Cai, Amulya Uppala, Saleem Shariff, Jurriaan Brouwer-Visser, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, Tae Min Kim. Primary analysis of the Phase 2 ELM-2 study: Odronextamab in patients (pts) with relapsed/refractory follicular lymphoma (R/R FL) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl):Abstract nr CT243.
Phase II Trial of Cisplatin, Gemcitabine, and Intensity-Modulated Radiation Therapy for Locally Advanced Vulvar Squamous Cell Carcinoma: NRG Oncology/GOG Study 279
Horowitz, Neil S. , Peterson, I., Mannel, Robert S., Thompson, J. S. , Lokich, Elizabeth, Myers, Tashanna , Hanjani, P., O’Malley, David M. , Chung, Ki Y. , Miller, David S. , Dizon, Don S. , Mayadev, Jyoti , Monk, Bradley J. , Peterson, Ivy, Thompson, Spencer , Myers, Tashanna , O'Malley, David M , Miller, David S , Ueland, Frederick R , Dizon, Don S , Miller, Austin , Mayadev, Jyoti S , Leath, Charles A , Monk, Bradley J , Deng, Wei, Miller, Austin

Mayo Clinic

Journal of Clinical Oncology | April 4, 2024 | Volume: 42 | Issue: 16 | Pages: 1914-1921

10.1200/jco.23.02235 | PMID 38574312 Get It

PURPOSE To assess efficacy and toxicity of cisplatin (C) and gemcitabine (G) with intensity-modulated radiation therapy (IMRT) in patients with locally advanced vulvar cancer not amenable to surgery. METHODS Patients enrolled in a single-arm phase II study. Pretreatment inguinal-femoral nodal assessment was performed. Sixty-four Gy IMRT was prescribed to the vulva, with 50-64 Gy delivered to the groins/low pelvis. Radiation therapy (RT) plans were quality-reviewed pretreatment. C 40 mg/m2 and G 50 mg/m2 were administered once per week throughout IMRT. Complete pathologic response (CPR) was the primary end point. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method, and adverse events were assessed with Common Terminology Criteria for Adverse Events v 4.0. RESULTS Fifty-seven patients enrolled, of which 52 were evaluable. The median age was 58 years (range, 25-58), and 94% were White. Forty (77%) had stage II or III disease, and all had squamous histology. A median of six chemotherapy cycles (range, 1-8) were received. Eighty-five percent of RT plans were quality-reviewed with 100% compliance to protocol. Seven patients came off trial because of toxicity or patient withdrawal. Of 52 patients available for pathologic assessment, 38 (73% [90% CI, 61 to 83]) achieved CPR. No pelvic exenterations were performed. With a median follow-up of 51 months, the 12-month PFS was 74% (90% CI, 62.2 to 82.7) and the 24-month OS was 70% (90% CI, 57 to 79). The most common grade 3 or 4 adverse events were hematologic toxicity and radiation dermatitis. There was one grade 5 event unlikely related to treatment. CONCLUSION Weekly C and G concurrent with IMRT sufficiently improved CPR in women with locally advanced vulvar squamous cell carcinoma not amenable to surgical resection.
Industry payments to American Society of Hematology Clinical Practice Guideline authors
Jacobs, Jeremy W. , Booth, Garrett S. , Adkins, Brian D. , Martin, Amarilis , Lundberg, George D., Glover, Raeshun T, Khan, Shazia S , Jacobs, Jeremy W , Booth, Garrett , Adkins, Brian David , Stephens, Laura D. , Silver, Julie K. , Woo, Jennifer S.

Mayo Clinic

Blood Advances | April 3, 2024 | Volume: 8 | Issue: 13 | Pages: 3549-3552

10.1182/bloodadvances.2023012527 | PMID 38569136 Get It

CSF biomarkers of immune activation and Alzheimer’s disease for predicting cognitive impairment risk in the elderly
Shue, Francis , White, Launia J. , Hendrix, Rachel , Ulrich, Jason D. , Henson, Rachel L. , Knight, William D., Martens, Yuka A. , Wang, Ni , Starling, Skylar C , Ren, Yingxue , Asmann, Yan W. , Syrjanen, Jeremy A. , Vassilaki, Maria , Sung, Yun Ju , Petersen, Ronald C. , Kanekiyo, Takahisa , Ulrich, Jason , Asmann, Yan W , Syrjanen, Jeremy A , Vassilaki, Maria , Mielke, Michelle M , Timsina, Jigyasha , Sung, Yun Ju , Cruchaga, Carlos , Holtzman, David M , Bu, Guojun , Petersen, Ronald C , Kanekiyo, Takahisa , Shue, Francis , Roy, Bhaskar, Xiong, Chengjie , Mielke, Michelle M. , Holtzman, David M. , Bu, Guojun , Heckman, Michael G.

Mayo Clinic

Science Advances | April 3, 2024 | Volume: 10 | Issue: 14 | Pages: No page available

10.1126/sciadv.adk3674 | PMID 38569027 Get It

The immune system substantially influences age-related cognitive decline and Alzheimer’s disease (AD) progression, affected by genetic and environmental factors. In a Mayo Clinic Study of Aging cohort, we examined how risk factors like APOE genotype, age, and sex affect inflammatory molecules and AD biomarkers in cerebrospinal fluid (CSF). Among cognitively unimpaired individuals over 65 ( N = 298), we measured 365 CSF inflammatory molecules, finding age, sex, and diabetes status predominantly influencing their levels. We observed age-related correlations with AD biomarkers such as total tau, phosphorylated tau-181, neurofilament light chain (NfL), and YKL40. APOE4 was associated with lower Aβ42 and higher SNAP25 in CSF. We explored baseline variables predicting cognitive decline risk, finding age, CSF Aβ42, NfL, and REG4 to be independently correlated. Subjects with older age, lower Aβ42, higher NfL, and higher REG4 at baseline had increased cognitive impairment risk during follow-up. This suggests that assessing CSF inflammatory molecules and AD biomarkers could predict cognitive impairment risk in the elderly.
Antibody-mediated targeting of human microglial leukocyte Ig-like receptor B4 attenuates amyloid pathology in a mouse model
Hou, Jinchao , Chen, Yun , Cai, Zhangying , Heo, Gyu Seong , Yuede, Carla M. , Wang, Z , Lin, Kent , Saadi, Fareeha , Tršan, Tihana , Nguyen, Aivi T. , Constantopoulos, Eleni , Larsen, Rachel A. , Zhu, Yiyang , Wagner, Nicole D. , McLaughlin, Nolan, Kuang, Xinyi Cynthia, Barrow, Alexander D. , Zhou, Yingyue , Gilfillan, Susan , Gross, Michael L. , Brioschi, Simone , Liu, Yongjian , Wang, Zuoxu , Li, Dian , Zhou, Yingyue , Wang, Shoutang , Gilfillan, Susan , Gross, Michael L , Brioschi, Simone , Liu, Yongjian , Holtzman, David M , Colonna, Marco , Nguyen, Aivi T , Holtzman, David M. , Colonna, Marco

Mayo Clinic

Science Translational Medicine | April 3, 2024 | Volume: 16 | Issue: 741 | Pages: No page available

10.1126/scitranslmed.adj9052 | PMID 38569016 Get It

Microglia help limit the progression of Alzheimer’s disease (AD) by constraining amyloid-β (Aβ) pathology, effected through a balance of activating and inhibitory intracellular signals delivered by distinct cell surface receptors. Human leukocyte Ig-like receptor B4 (LILRB4) is an inhibitory receptor of the immunoglobulin (Ig) superfamily that is expressed on myeloid cells and recognizes apolipoprotein E (ApoE) among other ligands. Here, we find that LILRB4 is highly expressed in the microglia of patients with AD. Using mice that accumulate Aβ and carry a transgene encompassing a portion of the LILR region that includes LILRB4 , we corroborated abundant LILRB4 expression in microglia wrapping around Aβ plaques. Systemic treatment of these mice with an anti-human LILRB4 monoclonal antibody (mAb) reduced Aβ load, mitigated some Aβ-related behavioral abnormalities, enhanced microglia activity, and attenuated expression of interferon-induced genes. In vitro binding experiments established that human LILRB4 binds both human and mouse ApoE and that anti-human LILRB4 mAb blocks such interaction. In silico modeling, biochemical, and mutagenesis analyses identified a loop between the two extracellular Ig domains of LILRB4 required for interaction with mouse ApoE and further indicated that anti-LILRB4 mAb may block LILRB4-mApoE by directly binding this loop. Thus, targeting LILRB4 may be a potential therapeutic avenue for AD.
US Liver Transplant Outcomes After Normothermic Regional Perfusion vs Standard Super Rapid Recovery
Sellers, Marty T., Abt, Peter L. , Merani, Shaheed , Alebrahim, Musab, Baskin, Roy H., Cederquist, K., Huerter, Benjamin G., Kautzman, Lori, Langnas, Alan N. , Manzi, João , Nassar, Ahmed , Neidlinger, Nikole , Nydam, Trevor L. , Siddiqui, Farjad , Suah, Ashley, Taj, Raeda , Testa, Giuliano , Vianna, Rodrigo , Vyas, Frederick, Montenovo, Martin I. , Taner, C. Burcin , Brubaker, Aleah L. , Croome, Kristopher P. , Wall, Anji , Abreu, Phillipe , Bohorquez, Humberto E. , Cannon, Robert M. , Edwards, John G. , Hobeika, Mark J. , Lee, David D. , Schnickel, Gabriel T

Mayo Clinic

JAMA Surgery | April 3, 2024 | Volume: 159 | Issue: 6 | Pages: 677

10.1001/jamasurg.2024.0520 | PMID 38568597 Get It

Importance Normothermic regional perfusion (NRP) is an emerging recovery modality for transplantable allografts from controlled donation after circulatory death (cDCD) donors. In the US, only 11.4% of liver recipients who are transplanted from a deceased donor receive a cDCD liver. NRP has the potential to safely expand the US donor pool with improved transplant outcomes as compared with standard super rapid recovery (SRR). Objective To assess outcomes of US liver transplants using controlled donation after circulatory death livers recovered with normothermic regional perfusion vs standard super rapid recovery. Design, Setting, and Participants This was a retrospective, observational cohort study comparing liver transplant outcomes from cDCD donors recovered by NRP vs SRR. Outcomes of cDCD liver transplant from January 2017 to May 2023 were collated from 17 US transplant centers and included livers recovered by SRR and NRP (thoracoabdominal NRP [TA-NRP] and abdominal NRP [A-NRP]). Seven transplant centers used NRP, allowing for liver allografts to be transplanted at 17 centers; 10 centers imported livers recovered via NRP from other centers. Exposures cDCD livers were recovered by either NRP or SRR. Main Outcomes and Measures The primary outcome was ischemic cholangiopathy (IC). Secondary end points included primary nonfunction (PNF), early allograft dysfunction (EAD), biliary anastomotic strictures, posttransplant length of stay (LOS), and patient and graft survival. Results A total of 242 cDCD livers were included in this study: 136 recovered by SRR and 106 recovered by NRP (TA-NRP, 79 and A-NRP, 27). Median (IQR) NRP and SRR donor age was 30.5 (22-44) years and 36 (27-49) years, respectively. Median (IQR) posttransplant LOS was significantly shorter in the NRP cohort (7 [5-11] days vs 10 [7-16] days; P < .001). PNF occurred only in the SRR allografts group (n = 2). EAD was more common in the SRR cohort (123 of 136 [56.1%] vs 77 of 106 [36.4%]; P = .007). Biliary anastomotic strictures were increased 2.8-fold in SRR recipients (7 of 105 [6.7%] vs 30 of 134 [22.4%]; P = .001). Only SRR recipients had IC (0 vs 12 of 133 [9.0%]; P = .002); IC-free survival by Kaplan-Meier was significantly improved in NRP recipients. Patient and graft survival were comparable between cohorts. Conclusion and Relevance There was comparable patient and graft survival in liver transplant recipients of cDCD donors recovered by NRP vs SRR, with reduced rates of IC, biliary complications, and EAD in NRP recipients. The feasibility of A-NRP and TA-NRP implementation across multiple US transplant centers supports increasing adoption of NRP to improve organ use, access to transplant, and risk of wait-list mortality.